For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
Occasional mild injection site reactions may occur
For body composition and cholesterol, certainty was also moderate for similar reasons
I suspect it will be some time before we get a trial with semaglutide or Tirzepatide to really understand whether a direct brain level is needed
Trusted by clients worldwide Consistent clinical care focused on safety, formulation, and outcomes